News
-
According to Consort Medical’s financial report for the fiscal year ending April 2014, its Bespak subsidiary is adding a 4,200 sq m facility for the manufacture of a nicotine DPI and a 5,200 sq m… Read more . . .
-
Discovery Laboratories says that it will use the $1.9 million it has received from the National Heart, Lung, and Blood Institute (NHLBI) for a Phase 2a trial of Aerosurf inhaled KL4 surfactant that is already… Read more . . .
-
GlaxoSmithKline and Theravance have announced that two Phase 3 studies have shown that COPD patients using the Incruse Ellipta umeclidinium (UMEC) DPI in conjunction with the Breo/Relvar Ellipta fluticasone furoate/vilanterol (FF/VI) DPI achieved a statistically… Read more . . .
-
AstraZeneca has paid $7.25 million up-front with potential milestone payments of up to $225 million for a global licence from Synairgen for its SNG001 inhaled interferon beta for the treatment of viral respiratory tract infections… Read more . . .
-
OptiNose has announced three hires for senior management positions, which it says “will help drive the company forward in its mission to introduce new and valuable treatment options to the market utilizing its novel Bi-Directional… Read more . . .
-
Strativa Pharmaceuticals has announced that it has received FDA approval for its disposable single-dose device version of Nascobal cyanocobalamin nasal spray for the treatment of pernicious anemia and other vitamin B12 deficiencies. The new product… Read more . . .
-
CDMO Pharmaterials has announced that it will quadruple its GMP manufacturing capacity and add a dedicated inhalation development laboratory as part of an expansion of its Reading, UK site. The expansion plans also include additions… Read more . . .
-
Avanir Pharmaceuticals and OptiNose have announced that a Phase 3b trial demonstrated that acute migraine patients experienced greater pain relief within 30 minutes of dosing using Avanir’s AVP-825 intranasal sumatriptan powder than patients taking sumatriptan… Read more . . .
-
Aradigm has received a $5 million milestone payment from Grifols as the ORBIT-3 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) trial of Pulmaquin inhaled ciprofloxacin for the treatment of non-cystic fibrosis bronchiectasis gets underway, the company announced.… Read more . . .
-
According to Smartinhaler manufacturer Nexus6, the FDA has granted 510(k) marketing clearance for a new version of the inhaler monitoring system called SmartTouch. The system includes a touch screen on the monitoring device and is… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.